Turning the focus to advanced-stage HCC, Tanios S. Bekaii-Saab, MD, offers comprehensive insights on first- and second-line treatment options.
Rintatolimod/Durvalumab Dose Appears Tolerable in Pancreatic Cancer
Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.
Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care
Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.
Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers
Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.
Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates
Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
COVID-19 Pandemic Has Exacerbated CRC Surgery Disparities
Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.